Essential thrombocythemia vs. early/prefibrotic myelofibrosis: Why does it matter

Best Practice and Research: Clinical Haematology

Volumn 27, Issue 2, 2014, Pages 129-140

  Barosi, Giovanni ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Bone marrow biopsy; Early prefibrotic myelofibrosis; Essential throbocythemia; Primary myelofibrosis

Indexed keywords

COLLAGEN; HEMOGLOBIN; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LACTATE DEHYDROGENASE; RETICULIN; TRANSCRIPTION FACTOR NF E2; JAK2 PROTEIN, HUMAN; MPL PROTEIN, HUMAN; NFE2 PROTEIN, HUMAN; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT;

ARTERY THROMBOSIS; ARTICLE; BLAST TRANSFORMATION; BONE MARROW BIOPSY; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLONAL VARIATION; DYSPLASIA; ENDOTHELIAL PROGENITOR CELL; EXTRAMEDULLARY HEMATOPOIESIS; GENE MUTATION; GRANULOCYTE; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPLASIA; IN VITRO STUDY; LEUKEMIA; LEUKOCYTE COUNT; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOLECULARLY TARGETED THERAPY; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOSIS; VEIN THROMBOSIS; ADULT; BONE MARROW CELL; CHEMISTRY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

ADULT; BONE MARROW CELLS; CELL PROLIFERATION; COLLAGEN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; NF-E2 TRANSCRIPTION FACTOR, P45 SUBUNIT; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; RECEPTORS, THROMBOPOIETIN; RETICULIN; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84925408151     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2014.07.004     Document Type: Review

References (57)

1. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of hematopoietic and lymphoid tissues. Lyon: IARC; 2008.
2. Laszlo J. Myeloproliferative disorders (MPD) : Myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. Semin Hematol 1975; 2: 409-32.
3. Barosi G, Ambrosetti A, Finelli C, et al. The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. Br J Haematol 1999; 104: 730-7.
4. Thiele J, Georgii A, Vykoupil KF. Ultrastructure of chronic megakaryocytic-granulocytic myelosis. Blut 1976; 32: 433-8.
5. Georgii A, Vykoupil KF, Thiele J. Chronic megakaryocytic granulocytic myelosis-CMGM. A subtype of chronic myeloid leukemia. Virchows Arch A Pathol Anat Histol 1980; 389: 253-68.
6. Georgii A. Histopathology of bone marrow in human chronic leukemias. Haematol Blood Transfus 1979; 23: 59-70.
7. Thiele J, Zankovich R, Steinberg T, et al. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosisea critical evaluation of clinical and histomorphological data. Acta Haematol 1989; 81: 192-202.
8. Thiele J, Steinberg T, Zankovich R, et al. Primary myelofibrosis-osteomyelosclerosis (agnogenic myeloid metaplasia) : Correlation of clinical findings with bone marrow histopathology and prognosis. Anticancer Res 1989; 9: 429-35.
9. Thiele J, Kvasnicka HM, Diehl V, et al. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 1999; 33: 207-18.
10. Michiels JJ, Kutti J, Stark P, et al. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Neth J Med 1999; 54: 46-62.
11. Kvasnicka HM, Thiele J. Prodromalmyeloproliferative neoplasms: The 2008WHO classification. AmJ Hematol 2010; 85: 62-9.
12. Thiele J, Vardiman JW, Pierre R, et al. Chronic idiopathic myelofibrosis. In: Jaffe E, Harris NL, Stein HS, et al., editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissue. World Health Organization classification of tumours. Lyon: IARC Press; 2001. pp. 35-8.
13. Wilkins BS, Erber WN, Bareford D, et al. Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes. Blood 2008; 111: 60-70.
14. Buhr T, Hebeda K, Kaloutsi V, et al. European bone marrow working group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica 2012; 97: 360-5.
15. Koopmans SM, Bot FJ, Lam KH, et al. Reproducibility of histologic classification in nonfibrotic myeloproliferative neoplasia. Am J Clin Pathol 2011; 136: 618-24.
16. Brousseau M, Parot-Schinkel E, Moles MP, et al. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis. Histopathology 2010; 56: 758-67.
17. Florena AM, Tripodo C, Iannitto E, et al. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. Haematologica 2004; 89: 911-9.
18. Gianelli U, Vener C, Raviele PR, et al. Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. Leuk Lymphoma 2006; 47: 1774-81.
19. Buhr T, Georgii A, Schuppan O, et al. Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts. Ann Hematol 1992; 64: 286-91.
20. Kreft A, Büche G, Ghalibafian M, et al. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: A retrospective evaluation of sequential bone marrow biopsies. Acta Haematol 2005; 113: 137-43.
21. Thiele J, Kvasnicka HM, Müllauer L, et al. Essential thrombocythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification. Blood 2011; 117: 5710-8.
22. Barosi G, Vannucchi AM, De Stefano V, et al. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: A consensus-based SIE, SIES, GITMO position paper. Leuk Res 2014; 38: 155-60.
23. Kreipe H, Jaquet K, Felgner J, et al. Clonal granulocytes and bone marrow cells in the cellular phase of agnogenic myeloid metaplasia. Blood 1991; 78: 1814-7.
24. Shih LY, Lin TL, Dunn P, et al. Clonality analysis using X-chromosome inactivation patterns by HUMARA-PCR assay in female controls and patients with idiopathic thrombocytosis in Taiwan. Exp Hematol 2001; 29: 202-8.
25. Harrison CN, Gale RE, Machin SJ, et al. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999; 93: 417-24.
26. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90.
27. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-97.
28. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-8.
29. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61.
30. Rumi E, Pietra D, Guglielmelli P, et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood 2013; 121: 4388-95.
31. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-90.
32. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-405.
33. Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861-9.
34. Hussein K, Bock O, Theophile K, et al. JAK2 (V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol 2009; 37: 1186-93.
35. Risum M, Madelung A, Bondo H, et al. The JAK2V617F allele burden and STAT3-and STAT5 phosphorylation in myeloproliferative neoplasms: Early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis. Acta Pathol Microbiol Immunol Scand 2011; 119: 498-504.
36. Goerttler PS, Kreutz C, Donauer J, et al. Gene expression profiling in polycythaemia vera: Overexpression of transcription factor NF-E2. Br J Haematol 2005; 129: 138-50.
37. Wang W, Schwemmers S, Hexner EO, et al. AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood 2010; 116: 254-66.
38. Aumann K, Frey AV, May AM, et al. Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia. Blood 2013; 122: 93-9.
39. Balduini A, Badalucco S, Pugliano MT, et al. In vitro megakaryocyte differentiation and proplatelet formation in Phnegative classical myeloproliferative neoplasms: Distinct patterns in the different clinical phenotypes. PLoS One 2011; 6: E21015.
40. Rosti V, Bonetti E, Bergamaschi G, et al. High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. PLoS One 2010; 5: E15277.
41. Critser PJ, Yoder MC. Endothelial colony-forming cell role in neoangiogenesis and tissue repair. Curr Opin Organ Transplant 2010; 15: 68-72.
42. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study. J Clin Oncol 2011; 29: 3179-84.
43. Barbui T, Thiele J, Carobbio A, et al. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 2012; 120: 569-71.
44. Carobbio A, Finazzi G, Thiele J, et al. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. Am J Hematol 2012; 87: 203-4.
45. Barosi G, Rosti V, Bonetti E, et al. Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis. PLoS One 2012; 7: E35631.
46. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708-14.
47. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-34.
48. Allegra A, Alonci A, Penna G, et al. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: The role of bone marrow biopsy for the diagnosis of myeloproliferative disease. Acta Haematol 2009; 121: 218-20.
49. Pagliuca A, Mufti GJ, Janossa-Tahernia M, et al. In vitro colony culture and chromosomal studies in hepatic and portal vein thrombosis-possible evidence of an occult myeloproliferative state. Q J Med 1990; 76: 981-9.
50. Orr DW, Patel RK, Lea NC, et al. The prevalence of the activating JAK2 tyrosine kinase mutation in chronic portosplenomesenteric venous thrombosis. Aliment Pharmacol Ther 2010; 31: 1330-6.
51. Barosi G, Buratti A, Costa A, et al. An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer 1991; 68: 2310-8.
52. Gong X, Lu X, Xiao X, et al. Clinicopathologic characteristics of prefibrotic-early primary myelofibrosis in Chinese patients. Hum Pathol 2014; 45: 498-503.
53. Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia 2012; 26: 716-9.
54. Buxhofer-Ausch V, Gisslinger H, Thiele J, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHOdefined early/prefibrotic myelofibrosis: An international study of 264 patients. Am J Hematol 2012; 87: 669-72.
55. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761-70.
56. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-901.
57. Barbui T, Thiele J, Vannucchi AM, et al. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia 2013; 27: 1953-8.